Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt No Debt
NSPR's Cash-to-Debt is ranked higher than
87% of the 335 Companies
in the Global Medical Devices industry.

( Industry Median: 2.54 vs. NSPR: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NSPR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.23  Med: 30.11 Max: No Debt
Current: No Debt
Equity-to-Asset 0.73
NSPR's Equity-to-Asset is ranked higher than
65% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. NSPR: 0.73 )
Ranked among companies with meaningful Equity-to-Asset only.
NSPR' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.69  Med: 0.19 Max: 0.78
Current: 0.73
-1.69
0.78
Piotroski F-Score: 5
Altman Z-Score: -18.51
Beneish M-Score: -3.76
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -403.37
NSPR's Operating Margin % is ranked lower than
88% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. NSPR: -403.37 )
Ranked among companies with meaningful Operating Margin % only.
NSPR' s Operating Margin % Range Over the Past 10 Years
Min: -840.95  Med: -365.91 Max: -228.66
Current: -403.37
-840.95
-228.66
Net Margin % -442.63
NSPR's Net Margin % is ranked lower than
88% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. NSPR: -442.63 )
Ranked among companies with meaningful Net Margin % only.
NSPR' s Net Margin % Range Over the Past 10 Years
Min: -890.53  Med: -523.57 Max: -244.25
Current: -442.63
-890.53
-244.25
ROE % -442.68
NSPR's ROE % is ranked lower than
98% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. NSPR: -442.68 )
Ranked among companies with meaningful ROE % only.
NSPR' s ROE % Range Over the Past 10 Years
Min: -1539.76  Med: -405.67 Max: -200
Current: -442.68
-1539.76
-200
ROA % -106.07
NSPR's ROA % is ranked lower than
90% of the 336 Companies
in the Global Medical Devices industry.

( Industry Median: 0.33 vs. NSPR: -106.07 )
Ranked among companies with meaningful ROA % only.
NSPR' s ROA % Range Over the Past 10 Years
Min: -436.36  Med: -230.92 Max: -80
Current: -106.07
-436.36
-80
ROC (Joel Greenblatt) % -1843.01
NSPR's ROC (Joel Greenblatt) % is ranked lower than
88% of the 333 Companies
in the Global Medical Devices industry.

( Industry Median: 5.51 vs. NSPR: -1843.01 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NSPR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -8439.86  Med: -2238.93 Max: -1484.91
Current: -1843.01
-8439.86
-1484.91
3-Year Revenue Growth Rate -71.60
NSPR's 3-Year Revenue Growth Rate is ranked lower than
97% of the 243 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. NSPR: -71.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NSPR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -71.6 Max: -41.4
Current: -71.6
3-Year EBITDA Growth Rate -73.80
NSPR's 3-Year EBITDA Growth Rate is ranked lower than
98% of the 214 Companies
in the Global Medical Devices industry.

( Industry Median: 5.60 vs. NSPR: -73.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NSPR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -73.8  Med: -9 Max: 685.3
Current: -73.8
-73.8
685.3
3-Year EPS without NRI Growth Rate -74.30
NSPR's 3-Year EPS without NRI Growth Rate is ranked lower than
98% of the 212 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. NSPR: -74.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NSPR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -40.1 Max: 370.7
Current: -74.3
0
370.7
GuruFocus has detected 1 Warning Sign with InspireMD Inc $NSPR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NSPR's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:OTCPK:ACXA, OTCPK:AROSF, NAS:MDGS, OTCPK:IGNG, OTCPK:MRLB, OTCPK:EQUR, NAS:CHFS, OTCPK:ACAR, OTCPK:VYCO, OTCPK:ESMC, NAS:PHMD, OTCPK:VRSEF, OTCPK:BIAD, OTCBB:GTHP, OTCPK:NUMD, OTCPK:MPHMF, OTCPK:PYNGF, OTCPK:PBIOD, NAS:AVGR, AMEX:MICR » details
Traded in other countries:II2N.Germany,
Headquarter Location:Israel
InspireMD Inc is a medical device company. The Company is engaged in the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease.

InspireMD Inc was organized in the State of Delaware on February 29, 2008 as Saguaro Resources, Inc. On March 28, 2011, it effectuated a 1-for-3 forward stock split and changed its name from Saguaro Resources, Inc. to InspireMD, Inc. It is an medical device company focusing on the development and commercialization of its proprietary stent platform technology, MGuard. MGuard provides embolic protection in stenting procedures by placing a micron mesh sleeve over a stent. The Company's initial products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). According to the TYPHOON STEMI trial and the SOS SVG Trial of patients with acute myocardial infarction and saphenous vein graft coronary interventions, 7.5% to 44% experience adverse cardiac events, including cardiac death, heart attack, and restenting of the artery. When performing stenting procedures in patients with acute coronary symptoms, interventional cardiologists face a difficult dilemma in choosing between bare-metal stents, which have a high rate of restenosis (formation of new blockages), and drug-eluting (drug-coated) stents, which have a high rate of late thrombosis (formation of clots months or years after implantation), require administration of anti-platelet drugs for at least one year post procedure, are more costly than bare-metal stents and have additional side effects. It intends to use its MGuard technology in a broad range of coronary related situations in which complex lesions are required and make it an industry standard for treatment of acute coronary syndromes. It also intends to apply its technology to develop additional products used for other vascular procedures, specifically carotid (the arteries that supply blood to the brain) and peripheral (other arteries) procedures. The Company markets its products through distributers in international markets, mainly in Europe and Latin America.

Top Ranked Articles about InspireMD Inc

InspireMD Announces Pricing of Public Offering of Approximately $14.6 Million

BOSTON, MA--(Marketwired - Jun 30, 2016) - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced the pricing of a "best efforts" public offering of approximately 442,424 shares of Series B Convertible Preferred Stock and accompanying warrants to purchase up to approximately 44,242,424 million shares of common stock. Each share of Series B Convertible Preferred Stock is convertible into 100 shares of common stock at a conversion price equal to $0.33 per share, and the holders of Series B Convertible Preferred Stock will be entitled to receive cumulative dividends at the rate per share of 15% per annum of the stated value for five years. The warrants shall be exercisable immediately and have a term of exercise of five years from the date of issuance and have an exercise price of $0.20 per share of common stock. The Company expects to receive gross proceeds of approximately $14.6 million from the offering, before deducting placement agent fees and estimated offering expenses payable by the Company, assuming completion of the maximum offering. The offering is expected to close on or about July 7, 2016, subject to customary closing conditions. The Company intends to use the net proceeds from the offering to conduct sales activities related to CGuard™ EPS™, MGuard Prime™ EPS and develop its pipeline of new products and for general corporate purposes. Dawson James Securities, Inc. is acting as the sole placement agent.  The securities intended to be sold in the offering described above are being offered pursuant to a registration statement on Form S-1 which was filed with the Securities and Exchange Commission ("SEC") and was declared effective on June 30, 2016. A final prospectus supplement relating to the offering will be filed with the SEC by July 1, 2016. Copies of the prospectus relating to the offering may be obtained from Dawson James Securities, Inc., Attention: Prospectus Department, 1 North Federal Highway, 5th Floor, Boca Raton, FL 33432, [email protected] or toll free at 866.928.0928. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About InspireMD, Inc. InspireMD seeks to utilize its proprietary MicroNet™ technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events. InspireMD intends to pursue applications of this MicroNet™ technology in coronary, carotid (CGuard™), neurovascular, and peripheral artery procedures. InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR. Forward-looking Statements This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.


Investor Contacts:

InspireMD, Inc.

Craig Shore

Chief Financial Officer

Phone: 1-888-776-6804 FREE

Email: [email protected]


PCG Advisory

Vivian Cervantes

Investor Relations

Phone: (212) 554-5482





Read more...
CORRECTION - InspireMD Announces Pricing of Public Offering of Approximately $14.6 Million

BOSTON, MA--(Marketwired - Jun 30, 2016) - In the news release, "InspireMD Announces Pricing of Public Offering of Approximately $14.6 Million," issued earlier today by InspireMD, Inc. (NYSE MKT: NSPR), we are advised by the company that in the first sentence of the first paragraph, it should read "44,242,424 shares" rather than "44,242,424 million shares" as originally issued. Complete corrected text follows. InspireMD Announces Pricing of Public Offering of Approximately $14.6 Million BOSTON, MA -- June 30, 2016 -- InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced the pricing of a "best efforts" public offering of approximately 442,424 shares of Series B Convertible Preferred Stock and accompanying warrants to purchase up to approximately 44,242,424 shares of common stock. Each share of Series B Convertible Preferred Stock is convertible into 100 shares of common stock at a conversion price equal to $0.33 per share, and the holders of Series B Convertible Preferred Stock will be entitled to receive cumulative dividends at the rate per share of 15% per annum of the stated value for five years. The warrants shall be exercisable immediately and have a term of exercise of five years from the date of issuance and have an exercise price of $0.20 per share of common stock. The Company expects to receive gross proceeds of approximately $14.6 million from the offering, before deducting placement agent fees and estimated offering expenses payable by the Company, assuming completion of the maximum offering. The offering is expected to close on or about July 7, 2016, subject to customary closing conditions. The Company intends to use the net proceeds from the offering to conduct sales activities related to CGuard™ EPS™, MGuard Prime™ EPS and develop its pipeline of new products and for general corporate purposes. Dawson James Securities, Inc. is acting as the sole placement agent.  The securities intended to be sold in the offering described above are being offered pursuant to a registration statement on Form S-1 which was filed with the Securities and Exchange Commission ("SEC") and was declared effective on June 30, 2016. A final prospectus supplement relating to the offering will be filed with the SEC by July 1, 2016. Copies of the prospectus relating to the offering may be obtained from Dawson James Securities, Inc., Attention: Prospectus Department, 1 North Federal Highway, 5th Floor, Boca Raton, FL 33432, [email protected] or toll free at 866.928.0928. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About InspireMD, Inc. InspireMD seeks to utilize its proprietary MicroNet™ technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events. InspireMD intends to pursue applications of this MicroNet™ technology in coronary, carotid (CGuard™), neurovascular, and peripheral artery procedures. InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR. Forward-looking Statements This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.


Investor Contacts:

InspireMD, Inc.

Craig Shore

Chief Financial Officer

Phone: 1-888-776-6804 FREE

Email: [email protected]



PCG Advisory

Vivian Cervantes

Investor Relations

Phone: (212) 554-5482





Read more...

Ratios

vs
industry
vs
history
PB Ratio 0.46
NSPR's PB Ratio is ranked higher than
97% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 3.01 vs. NSPR: 0.46 )
Ranked among companies with meaningful PB Ratio only.
NSPR' s PB Ratio Range Over the Past 10 Years
Min: 0.32  Med: 7.84 Max: 360.33
Current: 0.46
0.32
360.33
PS Ratio 0.28
NSPR's PS Ratio is ranked higher than
96% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.36 vs. NSPR: 0.28 )
Ranked among companies with meaningful PS Ratio only.
NSPR' s PS Ratio Range Over the Past 10 Years
Min: 0.28  Med: 9.92 Max: 98.75
Current: 0.28
0.28
98.75
EV-to-EBIT 0.61
NSPR's EV-to-EBIT is ranked higher than
99% of the 180 Companies
in the Global Medical Devices industry.

( Industry Median: 24.85 vs. NSPR: 0.61 )
Ranked among companies with meaningful EV-to-EBIT only.
NSPR' s EV-to-EBIT Range Over the Past 10 Years
Min: -49.4  Med: -2.55 Max: 0.8
Current: 0.61
-49.4
0.8
EV-to-EBITDA 0.63
NSPR's EV-to-EBITDA is ranked higher than
98% of the 187 Companies
in the Global Medical Devices industry.

( Industry Median: 18.30 vs. NSPR: 0.63 )
Ranked among companies with meaningful EV-to-EBITDA only.
NSPR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -50  Med: -2.55 Max: 0.9
Current: 0.63
-50
0.9
Current Ratio 4.24
NSPR's Current Ratio is ranked higher than
73% of the 331 Companies
in the Global Medical Devices industry.

( Industry Median: 2.59 vs. NSPR: 4.24 )
Ranked among companies with meaningful Current Ratio only.
NSPR' s Current Ratio Range Over the Past 10 Years
Min: 0.13  Med: 1.8 Max: 4.68
Current: 4.24
0.13
4.68
Quick Ratio 4.10
NSPR's Quick Ratio is ranked higher than
78% of the 331 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. NSPR: 4.10 )
Ranked among companies with meaningful Quick Ratio only.
NSPR' s Quick Ratio Range Over the Past 10 Years
Min: 0.13  Med: 1.68 Max: 4.28
Current: 4.1
0.13
4.28
Days Inventory 85.36
NSPR's Days Inventory is ranked higher than
72% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 131.96 vs. NSPR: 85.36 )
Ranked among companies with meaningful Days Inventory only.
NSPR' s Days Inventory Range Over the Past 10 Years
Min: 85.36  Med: 135.33 Max: 315.56
Current: 85.36
85.36
315.56
Days Sales Outstanding 90.48
NSPR's Days Sales Outstanding is ranked lower than
70% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 68.17 vs. NSPR: 90.48 )
Ranked among companies with meaningful Days Sales Outstanding only.
NSPR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 63.99  Med: 82.25 Max: 138.85
Current: 90.48
63.99
138.85
Days Payable 71.61
NSPR's Days Payable is ranked higher than
58% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 55.39 vs. NSPR: 71.61 )
Ranked among companies with meaningful Days Payable only.
NSPR' s Days Payable Range Over the Past 10 Years
Min: 71.61  Med: 112.28 Max: 132.86
Current: 71.61
71.61
132.86

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -119.50
NSPR's 3-Year Average Share Buyback Ratio is ranked lower than
97% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: -4.10 vs. NSPR: -119.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NSPR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -141  Med: -106.1 Max: -34.4
Current: -119.5
-141
-34.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 0.61
NSPR's Price-to-Net-Cash is ranked higher than
98% of the 112 Companies
in the Global Medical Devices industry.

( Industry Median: 15.77 vs. NSPR: 0.61 )
Ranked among companies with meaningful Price-to-Net-Cash only.
NSPR' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.61  Med: 12.06 Max: 110.32
Current: 0.61
0.61
110.32
Price-to-Net-Current-Asset-Value 0.53
NSPR's Price-to-Net-Current-Asset-Value is ranked higher than
99% of the 214 Companies
in the Global Medical Devices industry.

( Industry Median: 6.67 vs. NSPR: 0.53 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NSPR' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.51  Med: 13.76 Max: 80.94
Current: 0.53
0.51
80.94
Price-to-Tangible-Book 0.46
NSPR's Price-to-Tangible-Book is ranked higher than
97% of the 267 Companies
in the Global Medical Devices industry.

( Industry Median: 3.91 vs. NSPR: 0.46 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NSPR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.44  Med: 8.84 Max: 334.59
Current: 0.46
0.44
334.59
Price-to-Median-PS-Value 0.03
NSPR's Price-to-Median-PS-Value is ranked higher than
99% of the 276 Companies
in the Global Medical Devices industry.

( Industry Median: 1.04 vs. NSPR: 0.03 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NSPR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.03  Med: 1.01 Max: 9.18
Current: 0.03
0.03
9.18
Earnings Yield (Greenblatt) % 163.93
NSPR's Earnings Yield (Greenblatt) % is ranked higher than
99% of the 334 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. NSPR: 163.93 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NSPR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -2517.7  Med: -28.1 Max: 2652.7
Current: 163.93
-2517.7
2652.7

More Statistics

Revenue (TTM) (Mil) $1.90
EPS (TTM) $ -5.98
Beta1.23
Short Percentage of Float7.35%
52-Week Range $0.50 - 10.75
Shares Outstanding (Mil)7.42

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) -0.37
EPS without NRI ($) -0.37
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NSPR

Headlines

Articles On GuruFocus.com
InspireMD Announces Pricing of Public Offering of Approximately $14.6 Million Jun 30 2016 
CORRECTION - InspireMD Announces Pricing of Public Offering of Approximately $14.6 Million Jun 30 2016 
InspireMD Announces Amendment to Loan & Security Agreement With Hercules Capital Jun 14 2016 
InspireMD Names Dr. James Barry as President and CEO Jun 07 2016 
InspireMD Announces Late-Breaking Trial Presentation on CGuard(TM) Embolic Prevention System at Euro May 05 2016 
UPDATE: InspireMD Receives Audit Opinion With Going Concern Explanation Mar 31 2016 
Insiders Roundup: Sales on Facebook Mar 25 2016 
InspireMD Announces Closing of Public Offering Mar 21 2016 
InspireMD Announces Closing of Private Placement to Certain Officers and Directors Mar 21 2016 
InspireMD Announces Pricing of Public Offering Mar 16 2016 

More From Other Websites
InspireMD Announces Completion of Transition from Exclusive European Distributor to InspireMD... Jun 13 2017
InspireMD to Present at the 2017 Marcum Microcap Conference Jun 09 2017
InspireMD Announces Distribution Agreement for CGuard EPS in Taiwan Jun 08 2017
InspireMD Announces the Publication of an Investigator Initiated Clinical Registry Reaffirming... Jun 07 2017
InspireMD Announces Distribution Agreement for CGuard(TM) EPS in Poland Jun 05 2017
InspireMD Announces Appointment of Paul Stuka as Chairman of the Board Jun 02 2017
InspireMD to Present at the 6th Annual SeeThruEquity Microcap Investor Conference May 31 2017
InspireMD Announces First Two Patients in Hong Kong Successfully Treated with CGuard EPS May 30 2017
InspireMD's CGuard(TM) Carotid Embolic Prevention System Featured in Live Case Transmission at... May 18 2017
InspireMD Announces Publication of the IRON-GUARD Registry in EuroIntervention May 17 2017
InspireMD Announces Distribution Agreements for CGuard(TM) EPS and MGuard Prime(TM) EPS in Peru and... May 15 2017
InspireMD, Inc. :NSPR-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 May 12 2017
InspireMD Provides Business Update for the First Quarter of 2017 May 09 2017
InspireMD Schedules First Quarter 2017 Earnings Conference Call May 05 2017
InspireMD Announces Distribution Agreement for CGuard(TM) EPS in Germany May 01 2017
InspireMD Announces Distribution Agreement for CGuard(TM) EPS in the Netherlands Apr 06 2017
InspireMD Announces Listing of Series B Warrants on the NYSE MKT Apr 05 2017
InspireMD Announces Distribution Agreement for CGuardTM in Turkey Apr 04 2017
InspireMD Announces Commercial Launch of CGuard(TM) EPS in the Russian Federation at the ICCA Stroke... Mar 30 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}